Costa T - Search Results

1

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.

Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B. Høilund-Carlsen PF, et al. Among authors: costa t. Ageing Res Rev. 2024 Aug;99:102348. doi: 10.1016/j.arr.2024.102348. Epub 2024 Jun 1. Ageing Res Rev. 2024. PMID: 38830549 Review.

2

Passive Alzheimer's immunotherapy: A promising or uncertain option?

Høilund-Carlsen PF, Revheim ME, Costa T, Alavi A, Kepp KP, Sensi SL, Perry G, Robakis NK, Barrio JR, Vissel B. Høilund-Carlsen PF, et al. Among authors: costa t. Ageing Res Rev. 2023 Sep;90:101996. doi: 10.1016/j.arr.2023.101996. Epub 2023 Jul 5. Ageing Res Rev. 2023. PMID: 37414156 Review.

3

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.

Høilund-Carlsen PF, Revheim ME, Costa T, Kepp KP, Castellani RJ, Perry G, Alavi A, Barrio JR. Høilund-Carlsen PF, et al. Among authors: costa t. Diagnostics (Basel). 2023 Jul 3;13(13):2254. doi: 10.3390/diagnostics13132254. Diagnostics (Basel). 2023. PMID: 37443645 Free PMC article.

4

Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village.

Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B. Høilund-Carlsen PF, et al. Among authors: costa t. Ageing Res Rev. 2024 Jan;93:102173. doi: 10.1016/j.arr.2023.102173. Epub 2023 Dec 15. Ageing Res Rev. 2024. PMID: 38104639 Free article. Review.

5

Evaluating the robustness of DTI-ALPS in clinical context: a meta-analytic parallel on Alzheimer's and Parkinson's diseases.

Costa T, Manuello J, Premi E, Mattioli I, Lasagna L, Lahoz CB, Cauda F, Duca S, Liloia D. Costa T, et al. Sci Rep. 2024 Nov 2;14(1):26381. doi: 10.1038/s41598-024-78132-9. Sci Rep. 2024. PMID: 39487289 Free PMC article.

6

Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer's Disease Clinical Trials.

Costa T, Manuello J, Cauda F, Liloia D. Costa T, et al. J Alzheimers Dis. 2023;91(2):531-535. doi: 10.3233/JAD-220942. J Alzheimers Dis. 2023. PMID: 36442201

7

Unleashing the Power of Bayesian Re-Analysis: Enhancing Insights into Lecanemab (Clarity AD) Phase III Trial Through Informed t-Test.

Costa T, Premi E, Liloia D, Cauda F, Manuello J. Costa T, et al. J Alzheimers Dis. 2023;95(3):1059-1065. doi: 10.3233/JAD-230589. J Alzheimers Dis. 2023. PMID: 37638445 Clinical Trial.

8

Local functional connectivity abnormalities in mild cognitive impairment and Alzheimer's disease: A meta-analytic investigation using minimum Bayes factor activation likelihood estimation.

Costa T, Premi E, Borroni B, Manuello J, Cauda F, Duca S, Liloia D. Costa T, et al. Neuroimage. 2024 Sep;298:120798. doi: 10.1016/j.neuroimage.2024.120798. Epub 2024 Aug 15. Neuroimage. 2024. PMID: 39153521 Free article.

9

A Bayesian Reanalysis of the Phase III Aducanumab (ADU) Trial.

Costa T, Cauda F. Costa T, et al. J Alzheimers Dis. 2022;87(3):1009-1012. doi: 10.3233/JAD-220132. J Alzheimers Dis. 2022. PMID: 35404286 Clinical Trial.

10

Six actions to improve detection of critical features for neuroimaging coordinate-based meta-analysis preparation.

Manuello J, Costa T, Cauda F, Liloia D. Manuello J, et al. Among authors: costa t. Neurosci Biobehav Rev. 2022 Jun;137:104659. doi: 10.1016/j.neubiorev.2022.104659. Epub 2022 Apr 9. Neurosci Biobehav Rev. 2022. PMID: 35405181 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,631 results

Search Page

Filters